Related Experiment Video

Updated: Aug 9, 2026

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus
11:28

Dissecting Host-virus Interaction in Lytic Replication of a Model Herpesvirus

Published on: October 7, 2011

Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3

Megan J Dambach1, Jordan Trecki, Natalia Martin

  • 1Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 1, 2006
PubMed

Insights

Oncolytic herpes simplex virus (HSV-1) mutants used in cancer trials may develop unintended mutations. Researchers found a significant mutation in the UL3 gene during the creation of the R3616 oncolytic virus, highlighting the need for thorough characterization.

Area of Science:

  • Virology
  • Oncolytic Virotherapy
  • Molecular Biology

Background:

  • Replication-competent herpes simplex virus type 1 (HSV-1) mutants are utilized in clinical trials for experimental cancer treatment.
  • Key oncolytic HSV-1 mutants (G207, HSV1716, NV1020, Oncovex GM-CSF) share ICP34.5 gene defects, conferring neuroattenuation.

Purpose of the Study:

  • To investigate the occurrence of unintended mutations in oncolytic herpesviruses during their development.
  • To document the emergence of adventitious mutations in HSV-1 vectors intended for clinical use.

Main Methods:

  • Construction and characterization of the oncolytic herpes simplex virus (HSV-1) mutant R3616.
  • Genomic analysis to identify mutations in non-targeted regions of the HSV-1 genome.

Main Results:

  • A nonsense mutation was identified in an untargeted genomic region during the R3616 oncolytic virus construction.
  • This mutation led to a substantial truncation of the viral UL3 protein.
  • This is the first documented instance of adventitious mutations in oncolytic herpesviruses used in clinical trials.

Conclusions:

  • Oncolytic herpesviruses developed for clinical trials can acquire unexpected mutations.
  • Thorough characterization of viral vectors is crucial to ensure safety and efficacy.
  • Findings have implications for the development and regulatory approval of gene therapy vectors.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...